Compounds and uses thereof
The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.
1 . A compound having the structure of Formula I:
A-L-B Formula I,
wherein
L is a linker of the formula:
B is a degradation moiety of Formula A:
wherein
Y 1 is
R A5 is H or C 1 -C 6 alkyl;
one of R A1 , R A2 , R A3 , and R A4 is a bond between B and the linker and the others are H;
and
A has the structure of Formula II:
wherein
X 1 is CH;
X 2 , and X 3 are, independently, CH, or C(CH 3 );
R 1 is —SO 2 R 6 ;
R 2 and R 5 are each;
R 3 is H or a bond between A and the linker;
R 4 is H;
R 6 is C 1 -C 6 alkyl;
Het is
G 1 is
G 2 is absent,
and
A 1 is H or a bond between A and the linker,
provided that only one of R 3 and A 1 is a bond between A and the linker and the other is H,
or a pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 , wherein each of X 1 , X 2 , and X 3 is CH.
3 . The compound of claim 1 , wherein R 1 is
4 . A compound that has the structure of any one of the following compounds
#
Structure
2
3
5
6
7
8
9
11
12
13
15
16
20
21
22
23
24
28
29
30
36
38
41
42
43
45
46
51
52
53
54
55
57
58
59
60
64
66
67
68
73
81
82
83
84
90
91
92
93
95
96
97
101
102
103
104
105
106
111
112
115
122
125
127
128
129
131
133
139
143
144
147
148
149
152
161
162
167
168
169
172
184
185
186
187
223
228
229
230
252
253
258
271
272
273
274
275
276
277
278
280
281
282
283
286
287
288
289
290
291
292
293
295
296
or a pharmaceutically acceptable salt thereof.
5 . A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.